苦参素和甘利欣联用抗慢性乙型肝炎肝纤维化的临床研究

Clinical Research of Anti-hepatic Fibrosis in Chronic Hepatitis B by Combined Use of Oxymatrine and Diammonium Glycyrrihizinate

目的探讨苦参素和甘利欣联合治疗慢性乙型肝炎,在抗肝纤维化方面的疗效。方法将80例慢性乙型肝炎患者随机分为对照组、治疗组,对照组给予常规保肝治疗,治疗组在此基础上加用苦参素和甘利欣,治疗2个月,观察治疗前后两组患者的肝功能和血清肝纤维化指标的变化。结果两组患者治疗后肝功均明显改善,与治疗前比较差异有统计学意义(P<0.01或P<0.05);治疗组肝纤维化指标明显下降,前后比较差异有统计学意义(P<0.05),而对照组治疗前后差异无统计学意义(P>0.05);治疗后两组的总有效率比较差异有统计学意义(P<0.05)。结论两药联合治疗慢性乙型肝炎,可明显降低患者的血清肝纤维化指标,具有良好的抗肝纤维化作用。

Objective To discuss the clinical effect caused by oxymatrine and diammonium glycyrrihizinate in terms of anti-hepatic fibrosis in chronic hepatitis B patients.Methods Eighty patients were divided into treatment group and contrast group at random. The patients in contrast group were treated by conventional hepatic drugs,at the same time,oxymatrine and diammonium glycyrrihizinate are added in treatment group. After 2 months treatment,observe the change of clinical symptoms,signs,hepatic function,hepatic fibrosis marks. Results Hepatic function were significantly improved in two groups after treatment（P〈0.01）. Hepatic fibrosis marks were significantly reduced compared with those before treatment in the treatment group（P〈0.05）,There was no significant difference between the before and after treatment in the contrast group（P〉0.05）. The total effective rate of the two groups were significantly different after treatment（P〈0.05）.Conclusion Oxymatrine and diammonium glycyrrihizinate can effectively reduce the level of hepatic fibrosis marks in chronic hepatitis B patients. So the two drugs are effective in terms of anti-hepatic firosis.